Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia

Tokutaro Sato, Masao Oouchi, Hiroari Nagakubo, Tooru Chiba, Susumu Ogawa, Chiharu Sato, Kazuhiko Sugimura, Motosi Fukuda

研究成果: Article査読

7 被引用数 (Scopus)


Hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) is a common intermediate metabolite of cholesterol synthesis and ketone formation in the liver. In order to study the effect of HMG-CoA reductase inhibitor (pravastatin) on ketone formation, changes in the plasma levels of ketone bodies by treatment with pravastatin were studied in 18 non-insulin dependent diabetics with hypercholesterolemia. Body mass index, diabetic control, and plasma free fatty acid levels were not changed during the study, and the plasma levels of cholesterol decreased significantly from 250±25 to 211±34 mg/100 ml after 6 months of pravastatin treatment. The plasma levels of acetoacetic acid also significantly decreased from 37.7±22.6 to 28.4±13.4 μmol/l, and those of 3-hydroxybutyric acid and total ketone bodies also tended to decrease after pravastatin treatment. These results suggest that pravastatin decrease ketone formation in hepatic mitochondria besides cholesterol synthesis in hepatic microsone.

ジャーナルTohoku Journal of Experimental Medicine
出版ステータスPublished - 1998 5月

ASJC Scopus subject areas

  • 生化学、遺伝学、分子生物学(全般)


「Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。